AARON HOLDERMAN: Open Payments
NPI 1871863852 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,965 in 77 payments from 20 companies in 2025. Trend: 2023 $1,447 · 2024 $2,104 · 2025 $1,965
Food & beverage: $1,965
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $414 |
| Janssen Biotech, Inc. | 9 | $287 |
| Madrigal Pharmaceuticals | 6 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $212 |
| Regeneron Healthcare Solutions, Inc. | 2 | $136 |
| GENZYME CORPORATION | 4 | $121 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $93 |
| Gilead Sciences, Inc. | 3 | $81 |
| Lilly USA, LLC | 3 | $63 |
| QOL Medical, LLC | 3 | $63 |
Products named: TREMFYA, REZDIFFRA, ENTYVIO, RINVOQ, DUPIXENT, EYLEA HD, XIFAXAN, SKYRIZI.
Industry payments across IN — which companies pay providers there.
